Publications by authors named "P Panayiotidis"

MiRNAs have been identified as participants in leukemogenesis by controlling several cellular functions, such as differentiation, proliferation, and apoptosis. Their role in myelodysplastic neoplasms (MDS) pathogenesis is researched due to implementations in early identification, classification, and therapeutical options. IPSS-R, being the most widely used MDS classification, underestimates early biological events that can alter the disease's prognosis.

View Article and Find Full Text PDF

Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively.

View Article and Find Full Text PDF

Ankle pathology, such as severe arthritis, often necessitates surgical intervention to restore mobility and alleviate pain. Two commonly performed procedures for end-stage ankle disease are ankle fusion (AF) and total ankle arthroplasty (TAA). This review aims to compare the impact of AF and TAA on postoperative gait parameters.

View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the antibody response (AR) in 54 hematopoietic stem-cell transplantation (HSCT) recipients after receiving the BNT162b2 vaccine, showing an initial AR positivity rate of 80.8% at one month, which slightly decreased to 85.7% at three months.
  • Among the cohort, a significant number of participants achieved high antibody titers at both measurement points, but a noted decline in titers occurred from one month to three months post-vaccination.
  • Negative factors impacting AR included pre-treatment conditions like hypogammaglobulinemia and specific medications like anti-CD20 antibodies, suggesting HSCT patients can benefit from vaccination around six months post-transplant even in the
View Article and Find Full Text PDF